April 15, 2022
Astellas Pharma said on April 14 that its antibody drug conjugate (ADC) Padcev (enfortumab vedotin) was approved in Europe as a monotherapy for the treatment of certain patients with advanced urothelial cancer, the most common type of bladder cancer. The...read more